BSG and chronic myelogenous leukemia, BCR-ABL1 positive: In a mouse xenograft model inoculated with KU812 CML cells (with low sensitivity to imatinib), treatment with the anti-CD147 antibody exerted a 99% antitumor effect compared to the imatinib group (TGI 48%), resulting in complete tumor regression.